Honoree has shaped how the world understands and improves heart health - www.heart.org

BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced that it has been named to the 2026 “Endpoints 11” list of the most promising startups in the biopharmaceutical industry. The annual Endpoints News honor recognizes private companies that are pursuing the most ambitious scientific breakthroughs of tomorrow, backed by expert leadership and strong investor confidence. “At Corsera Health, we have a bold vision: a world without cardiovascular disease,” said John Maraganore, Ph. D., Co-Founder and Co-CEO. “We are pursuing this vision by combining early prediction of lifetime cardiovascular disease risk through Klotho, our proprietary AI-powered platform, with preventive medicines designed to address the major drivers of cardiovascular disease. Our first preventive RNAi medicine is advancing through Phase 1 clinical development, marking important progress toward bringing prediction and prevention together to advance a new approach to cardiovascular health.”

Granulomatosis with polyangiitis (GPA) is a systemic necrotizing granulomatous vasculitis classically involving the upper and lower respiratory tracts and kidneys. Timely diagnosis requires a high index of suspicion for the presenting symptoms. Otolaryngologic manifestations are commonly reported but most often involve the nasal and paranasal sinuses. Sensorineural hearing loss (SNHL) as the sole initial manifestation of GPA is uncommon and may contribute to diagnostic delay. We report a case of a 67-year-old male who presented with rapidly progressive bilateral SNHL that preceded pulmonary and renal manifestations by several months, during which the patient was treated for otitis externa and Eustachian tube dysfunction without improvement. Development of pulmonary symptoms prompted additional workup, which demonstrated markedly elevated cytoplasmic anti-neutrophil cytoplasmic antibody (c-ANCA) and proteinase 3-anti-neutrophil cytoplasmic antibody (PR3-ANCA), raising concern for GPA. Histopathology then confirmed the diagnosis. The patient was treated with high-dose corticosteroids and rituximab with serologic remission; however, his hearing loss was largely irreversible. This case

What if the human brain works in ways that Sigmund Freud began describing more than 130 years ago? A new scientific analysis suggests that some of his ideas about the mind share surprising similarities with one of the most influential theories in modern neuroscience. Published in the scientific journal Entropy, the paper explores connections between Freud's original theories, later developments in psychoanalysis, and a modern approach to brain research known as the prediction paradigm.